Day One Biopharmaceuticals Inks $130M Series B Financing

11 Feb, 2021

Day One Biopharmaceuticals Inks $130M Series B Financing
Photo by XPS on Unsplash

– Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating therapies for children and adults with cancer, announced a $130 million Series B financing.
– The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

Biopharma Biotechnology Health Care Medical North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: